hat
Pwoblèm lan se YK-11 gen absoliman okenn tès epi pa gen okenn chèchè ki gen lisans, konpayi pharma oswa Sarms konpayi te kontinye nenpòt rechèch sou li. YK te gen okenn Tès Animal (pa gen rat oswa sourit) ak evidamman pa gen okenn etid imen. YK sèlman gen nan done vitro sou selil C2C12 soti nan liy selil myoblast selil ki kapab diferansyasyon. Nan lòt mo, li te sèlman teste nan yon tib tès. Eksperyans sa a di nou ke li gen potansyèl pou lakòz difikilte nan misk nan konsantrasyon sèten. Men, sa pa ka tradui dirèkteman nan dòz imen paske gen 0 done sou metabolis li yo. Sepandan kounye a ke nou konnen li se yon esteroyetik sentetik ou ta ka diskite ke yon devine enfòme soti nan lòt estewoyid sentetik ta bay endikasyon ki graj nan metabolis li yo. Men, pa gen anyen konkrè ak sètènman pa gen anyen ki pwouve.
eng
The problem is YK-11 has absolutely no testing and no licenced researchers, pharma company or Sarms company has continued any research on it. YK has had No Animal testing (no rats or mice) and obviously no human studies. YK only has in vitro data on C2C12 cells from mice myoblast cell line capable of differentiation. In other words, it’s only been tested in a test tube. This experiment does tell us that it has the potential to cause muscle differentiation at certain concentrations. But this cannot be directly translated into human dosages because there is 0 data on its metabolism. However now that we know it is a synthetic steroid you could argue that an informed guess from other synthetic steroids would give rough indications of its metabolism. But nothing concrete and certainly nothing proved.